
Eli Lilly and Company
LLYAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 2, 2026 | Cantor Fitzgerald | Carter Gould | $1600.00(+14%) | $1409.22 | StreetInsider |
| Oct 30, 2026 | RBC Capital | $1600.00(+12%) | $1425.34 | StreetInsider | |
| Oct 30, 2026 | Argus Research | Jasper Hellweg | $1550.00(+13%) | $1373.00 | StreetInsider |
| Oct 30, 2026 | UBS | Michael Yee | $1625.00(+18%) | $1373.00 | StreetInsider |
| Oct 30, 2026 | BMO Capital | Evan Seigerman | $1650.00(+20%) | $1373.00 | StreetInsider |
| Oct 30, 2026 | KeyBanc | $1497.00(+9%) | $1373.00 | StreetInsider | |
| Oct 30, 2026 | Wells Fargo | Mohit Bansal | $1500.00(+9%) | $1373.00 | StreetInsider |
| Oct 30, 2026 | Truist Financial | Srikripa Devarakonda | $1612.00(+17%) | $1373.00 | StreetInsider |
| Oct 26, 2026 | Bernstein | Courtney Breen | $1450.00(+14%) | $1273.46 | TheFly |
| Oct 21, 2026 | Leerink Partners | $1316.00(+4%) | $1265.92 | TheFly | |
| Oct 20, 2026 | Goldman Sachs | $1413.00(+9%) | $1300.46 | TheFly | |
| Oct 8, 2026 | Cantor Fitzgerald | Carter Gould | $1440.00(+21%) | $1188.72 | TheFly |
| Oct 7, 2026 | Morgan Stanley | $1430.00(+21%) | $1184.47 | TheFly | |
| Sep 18, 2026 | Guggenheim | Seamus Fernandez | $1284.00(+11%) | $1152.13 | StreetInsider |
| Sep 15, 2026 | Berenberg Bank | Kerry Holford | $1400.00(+23%) | $1137.75 | StreetInsider |
| Sep 10, 2026 | HSBC | $940.00(-16%) | $1124.16 | TheFly | |
| Aug 7, 2026 | UBS | $1376.00(+17%) | $1177.33 | TheFly | |
| Aug 6, 2026 | Cantor Fitzgerald | $1410.00(+19%) | $1181.00 | TheFly | |
| Aug 6, 2026 | Morgan Stanley | $1419.00(+21%) | $1169.86 | TheFly | |
| Aug 6, 2026 | Wells Fargo | Mohit Bansal | $1330.00(+14%) | $1169.86 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Cantor Fitzgerald | maintain | Overweight | Nov 2, 2026 |
| Morgan Stanley | maintain | Overweight | Oct 30, 2026 |
| Scotiabank | maintain | Sector Outperform | Oct 30, 2026 |
| Citigroup | maintain | Buy | Oct 30, 2026 |
| JP Morgan | maintain | Overweight | Oct 30, 2026 |
| UBS | maintain | Buy | Oct 30, 2026 |
| Truist Securities | maintain | Buy | Oct 30, 2026 |
| RBC Capital | maintain | Outperform | Oct 30, 2026 |
| Argus Research | maintain | Buy | Oct 30, 2026 |
| Wells Fargo | maintain | Overweight | Oct 30, 2026 |
| Leerink Partners | maintain | Outperform | Oct 21, 2026 |
| RBC Capital | maintain | Outperform | Oct 12, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Oct 8, 2026 |
| Morgan Stanley | maintain | Overweight | Oct 7, 2026 |
| JP Morgan | maintain | Overweight | Sep 28, 2026 |
| TD Cowen | maintain | Buy | Sep 22, 2026 |
| Guggenheim | maintain | Buy | Sep 18, 2026 |
| HSBC | maintain | Reduce | Sep 10, 2026 |
| Truist Securities | maintain | Buy | Aug 7, 2026 |
| Wells Fargo | maintain | Overweight | Aug 6, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Aug 6, 2026 |
| Citigroup | maintain | Buy | Jul 15, 2026 |
| Bernstein | maintain | Outperform | Jul 14, 2026 |
| UBS | maintain | Buy | Jul 13, 2026 |
| Guggenheim | maintain | Buy | Jul 13, 2026 |
Earnings History
Next report: Feb 3, 2027 · EPS est. $11.20| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 29, 2026 | $7.48 | $5.71 | $24.40B | $22.58B |
| Aug 5, 2026 | $8.38 | $6.40 | $22.97B | $20.82B |
| Apr 30, 2026 | $8.55 | $6.97 | $19.80B | $17.82B |
| Feb 4, 2026 | $7.54 | $6.91 | $19.29B | $17.94B |
| Oct 30, 2025 | $7.02 | $5.69 | $17.60B | $16.05B |
| Aug 7, 2025 | $6.31 | $5.60 | $15.56B | $14.70B |
| May 1, 2025 | $3.34 | $3.26 | $12.73B | $12.67B |
| Feb 6, 2025 | $5.32 | $5.03 | $13.53B | — |
News
Some of Eli Lilly's products beyond its core therapeutic area are performing well. It also boasts a deep and diversified pipeline.
On Friday, Eli Lilly And Co. (NYSE:LLY) and Hims & Hers Health Inc. (NYSE:HIMS) announced a collaboration to broaden patient access to obesity medications Zepbound and Foundayo through the digital health platform.
The best mutual funds place massive bets on Microsoft, Palantir and Apple. But that's just the start.
Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices availab…
INDIANAPOLIS--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform. The agreement brings together Lilly's obesity med.
As tech stocks retreat, AbbVie (ABBV) and Eli Lilly (LLY) are hitting fresh 52-week highs, offering investors defensive healthcare exposure with compelling growth potential.
The massive AI-driven selloff is leaving investors looking for safe-haven stocks. Now might be a good time to consider buying Eli Lilly (LLY) stock for value and huge growth far outside of AI.
Eli Lilly's post-Q3 earnings rally highlights its surging drug demand. Discover 4 healthcare ETFs offering LLY exposure.
Eli Lilly just crushed earnings and raised guidance, yet the most compelling part of its story has almost nothing to do with what already happened.
Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee pain at the end of the trials Detailed Phase 3b TOGETHER-PsA data showed positive results across disease activity, patient-reported and metabolic outcomes at one year for Taltz and Zepbound vs. Taltz alone in adults with psoriatic arthritis and obesity INDIANAPOLIS, Nov. 5, 2026 /…
Caldwell Trust Co increased its stake in Eli Lilly and Company (NYSE: LLY) by 3.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,203 shares of the company's stock after buying an additional 653 shares during the period. Eli Lilly and
Compass Financial Management LLC grew its holdings in Eli Lilly and Company (NYSE: LLY) by 19.1% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,657 shares of the company's stock after acquiring an additional 427 shares during the quarter. Compass
Focused Wealth Management Inc trimmed its stake in shares of Eli Lilly and Company (NYSE: LLY) by 13.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,835 shares of the company's stock after selling 443 shares during the quarter. Focused Wealth
AIA Group Ltd trimmed its position in shares of Eli Lilly and Company (NYSE: LLY) by 11.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,479 shares of the company's stock after selling 6,337 shares during the quarter. Eli Lilly and Company
Eli Lilly is positioned as the primary beneficiary of AI-driven drug discovery, leveraging its scale and research infrastructure. LLY's integration of AI accelerates new molecule development, enabling rapid expansion of product lines and access to untapped markets. Despite a forward P/E of 40, I rate LLY a Buy for the next 2–3 years, anticipating investor euphoria and substantial earnings growth.
/PRNewswire/ -- Market Updates News Commentary - U.S. stock index futures were mixed early Wednesday after a split session on Tuesday. As of 2:22 a.m. ET,
Eli Lilly and Company delivered 39% revenue growth, driven by 53% volume gains despite a 15% decline in realized prices; gross margin rose to 83.9%. Eli Lilly's Strong Buy rating reflects robust growth, high margins, and strong momentum, but earnings were impacted by $4.57/share in acquired R&D charges. Two-thirds of revenue comes from tirzepatide (Mounjaro/Zepbound), heightening concentration risk as patent expiration looms and pricing pressure intensifies.
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly and Company's LLY stock has risen 9.6% since it announced solid third-quarter results on Oct. 29. Lilly's third-quarter earnings and revenues comfortably exceeded estimates.
Eli Lilly's weight-loss drugs get all the headlines, but CEO David Ricks is betting the company's next act looks nothing like its last one. Here is what it would actually take for shares to reach $1,700 in 2027.